Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Metta Medical Inc. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to a distinct examiner and a single art unit. SONG, JIANFENG is the busiest examiner for the portfolio, currently managing 1 pending office action. This means the entire current prosecution workload is handled by a single individual and a single specialized unit.
For a practitioner, this concentration allows for a targeted strategy focused on the specific examination style of the assigned examiner. With the current activity in the Biotechnology & Pharmaceuticals sector limited to a single point of contact, the outcome of this specific case is critical for the portfolio's immediate progress. The presence of a single art unit ensures that the review is conducted within a specialized technological framework, providing a consistent environment for the pending matter. This approach simplifies the management of the company's current patent interests.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SONG, JIANFENG | 1 | 56.4% | +33.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18820016 | Activated Cannabinoid Controlled Release Compound Tablet and Method of Forming The Same | SONG, JIANFENG | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18820016 | Activated Cannabinoid Controlled Release Compound Tablet and Method of Forming The Same | SONG, JIANFENG | 1613 | §103§112DP | Non-Final OA | — | Pending | Aug 29, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMetta Medical Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jianfeng Song has the most, with 1 of Metta Medical Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
